{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 6', 'Study Schematic', 'Up to', '52 weeks', '32 days', 'Placebo (n=50)', 'R', '2', 'Screening', 'Follow-up', '1', 'Danirixin, 35mg', '(n=50)', '1', 'If changes to medication are required, consent must be signed prior to', 'any changes being made and may occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Original text:', '6', 'Study Population', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764]. This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Amended text:', '6', 'Study Population', 'This study will identify specific COPD patients most likely to decline from well', 'established cohorts like COPDGene [NCT00608764]. This study will be an ancillary', 'study within COPDGene and any other relevant cohort investigating the enrichment', 'strategy for assessing disease progression. These potential participants will be identified', 'by COPDGene investigators based on data collected over the initial 5 year period. The', 'participants were identified based on a demonstrated decline of at least 15mL/yr over the', 'initial 5 year period. Once participants are identified from the COPDGene dataset, the', 'following criteria will be verified at initial study visit following signing of consent.', 'Equivalent cirteria may be identified within other cohorts if necessary to broaden', 'recruitment pool.', '110']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Original text:', 'Inclusion Criteria', 'Weight', '4. Body weight >45kg', 'Amended text:', 'Weight', '4, Body Mass Index > 21', 'Original text:', 'Exclusion Criteira', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin', '<35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Amended text:', 'Exclusion Criteria', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN) and bilirubin >', '1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and', 'direct bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Note:', 'Participants with positive Hepatitis C antibody due to prior resolved disease can be', '111']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Original text:', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1.', 'Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected.', '112']\n\n###\n\n", "completion": "END"}